BACKGROUND: Recurrent glioblastomas (GBMs) occasionally appear as disseminated or metastatic lesions at sites distant from the primary tumor, and clinical course of these GBMs is miserable. MicroRNAs (miRs) are small, noncoding RNAs, which regulate gene expression and various biological cellular events. The aim of this study is to clarify the miRs which promote dissemination or metastasis in GBMs. METHODS: Twenty-two supratentorial GBMs with leptomeningeal dissemination or metastasis to spinal cord or medulla oblongata (GBM with D/M) and 53 GBMs without D/M were analyzed. The expression levels of twenty-two miRs, which were known to be related to GBM, were examined using TaqMan real-time RT-PCR. After then, several miRs which were significantly upregulated or downregulated in GBMs with D/M were biologically examined by WST assay and migration assay, etc. RESULTS: Eight miRs (miR-7, -29b, -34a, -101, -124, -128a, -137, -218) were statistically decreased in GBM with D/M as compared with that without D/M. On the other hand, no miR was statistically increased in GBM with D/M. We focused on three miRs (miR-29b, miR-34a, and miR-101) that were most significantly decreased in GBM with D/M. Applying the mimic RNA for these miRs inhibited cell proliferation in WST assay and inhibited migration in migration assay in U87 and A172 glioma cells. In contrast, inhibitor of these miRs promoted cell migration in glioma cells. CONCLUSION: Expressions of several miRs (miR-29b, miR-34a, and miR-101) are characteristics in GBM with D/M. These miRs may be a predictive marker of dissemination or metastasis in GBMs.
. 2015 Nov 9;17(Suppl 5):v62–v63. doi: 10.1093/neuonc/nov209.38
CBIO-38: CHARACTERISTICS OF microRNA EXPRESSIONS IN GLIOBLASTOMA WITH LEPTOMENINGEAL DISSEMINATION OR METASTASIS
Takashi Sasayama
1, Mitsutoshi Nakada
2, Kazuhiro Tanaka
1, Naoya Hashimoto
3, Manabu Kinoshita
4, Naoki Kagawa
3, Katsu Mizukawa
1, Hirotomo Tanaka
1, Takashi Mizowaki
1, Hiroaki Nagashima
1, Junichi Sakata
1, Eiji Kohmura
1
Takashi Sasayama
1Department of Neurosurgery, Kobe University, Kobe, Japan
Find articles by Takashi Sasayama
Mitsutoshi Nakada
2Department of Neurosurgery, Kanazawa University, Kanazawa, Japan
Find articles by Mitsutoshi Nakada
Kazuhiro Tanaka
1Department of Neurosurgery, Kobe University, Kobe, Japan
Find articles by Kazuhiro Tanaka
Naoya Hashimoto
3Department of Neurosurgery, Osaka University, Osaka, Japan
Find articles by Naoya Hashimoto
Manabu Kinoshita
4Department of Neurosurgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
Find articles by Manabu Kinoshita
Naoki Kagawa
3Department of Neurosurgery, Osaka University, Osaka, Japan
Find articles by Naoki Kagawa
Katsu Mizukawa
1Department of Neurosurgery, Kobe University, Kobe, Japan
Find articles by Katsu Mizukawa
Hirotomo Tanaka
1Department of Neurosurgery, Kobe University, Kobe, Japan
Find articles by Hirotomo Tanaka
Takashi Mizowaki
1Department of Neurosurgery, Kobe University, Kobe, Japan
Find articles by Takashi Mizowaki
Hiroaki Nagashima
1Department of Neurosurgery, Kobe University, Kobe, Japan
Find articles by Hiroaki Nagashima
Junichi Sakata
1Department of Neurosurgery, Kobe University, Kobe, Japan
Find articles by Junichi Sakata
Eiji Kohmura
1Department of Neurosurgery, Kobe University, Kobe, Japan
Find articles by Eiji Kohmura
1Department of Neurosurgery, Kobe University, Kobe, Japan
2Department of Neurosurgery, Kanazawa University, Kanazawa, Japan
3Department of Neurosurgery, Osaka University, Osaka, Japan
4Department of Neurosurgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
Issue date 2015 Nov.
Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
PMCID: PMC4638680
